Breaking News
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - The Mount Sinai Hospital receives accreditation as geriatric emergency department
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
July 20, 2018 - Using miniature drug-filled nanocarriers to target headaches and tumors
July 20, 2018 - Researchers uncover cause for progression of prostate cancer to incurable stage
July 20, 2018 - Studies highlight issues regarding black lung, opioid overdose, police violence and more
July 20, 2018 - AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia
July 20, 2018 - Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
July 20, 2018 - Patients maintain muscle mass five years after surgically induced weight loss
July 20, 2018 - AMSBIO introduces new, powerful CRISPR/Cas9 gene editing kits
July 20, 2018 - PureTech Health collaborates with Roche to advance oral administration of antisense oligonucleotides
July 20, 2018 - Analysis reveals disparities in cancer death rates among minority groups
July 20, 2018 - Dr Maddy Parsons receives Royal Microscopical Society Life Science Medal
July 20, 2018 - Study finds link between DNA methylation and non-alcoholic fatty liver disease
July 20, 2018 - Military personnel with head trauma and football players with suspected CTE show similar brain changes
July 20, 2018 - Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
July 20, 2018 - KKR is buying Envision Healthcare in a nearly $10B deal
July 20, 2018 - Older people with broken bones face higher risk of death for up to 10 years
July 20, 2018 - A simple pill for meth addicts on the cards
July 20, 2018 - UA researchers to repurpose ketamine to reduce side effects in Parkinson’s patients
July 20, 2018 - Child psychiatrist available on call to help assess separated immigrant children
July 20, 2018 - High bitter-taste sensitivity linked to increased risk of cancer
July 20, 2018 - Falling temperatures may lead to rise in numbers of deaths from stroke
July 20, 2018 - Supplemental oxygen prevents rise in morning blood pressure in OSA patients
July 20, 2018 - High fruit and vegetable intake linked to reduced risk of breast cancer
July 20, 2018 - Careful patient selection may help achieve good outcomes for vaginal mesh surgery
July 20, 2018 - Researchers raise viability of cloned mice using somatic cell nuclear transfer method
July 20, 2018 - 3HP for Latent TB Infection Treatment | 2018 | Newsroom | NCHHSTP
No Efficacy Hit from Stopping Immunotherapy for AEs

No Efficacy Hit from Stopping Immunotherapy for AEs

image_pdfDownload PDFimage_print

Action Points

  • Efficacy outcomes were similar between patients who discontinued melanoma induction immunotherapy with nivolumab plus ipilimumab due to adverse events (AEs), and those who did not discontinue therapy.
  • Note that these pooled trial data suggest patients may continue to derive benefit even after treatment is stopped because of AEs, and response rate, depth of response, and overall survival do not seem to be diminished for these patients.

Patients who discontinued induction immunotherapy for advanced melanoma because of adverse events did just as well as those who continued treatment uninterrupted, a pooled analysis of randomized trials showed.

Patients who discontinued had an objective response rate of almost 60% compared with about 50% for those who finished induction therapy. Median progression-free survival (PFS) did not differ significantly between patients who discontinued and those who did not; median overall survival had yet to be reached in either group.

“Most patients who discontinued the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did so before receiving all four doses of the combination,” Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues concluded in the Journal of Clinical Oncology.

“Efficacy of nivolumab plus ipilimumab seemed to be similar for those who did and did not discontinue because of adverse events. This suggests that patients may continue to derive benefit from combination therapy even after treatment is stopped because of adverse events.”

Despite the preliminary nature of the data, the findings raised “thought-provoking questions about the possible impact of early treatment cessation in the setting of toxicity on the durability of response,” two Australian oncologists wrote in an accompanying editorial.

“Several key messages ave arisen from this work,” said Matteo S. Carlino, MD, of the University of Sydney, and Shaneen Sandhu, MD, of Peter MacCallum Cancer Center and the University of Melbourne, in the editorial. “The response rate, depth of response, and overall survival do not seem to be diminished for patients who discontinue treatment as a result of immune-related adverse events at induction.

“In addition, the use of immunomodulatory agents to manage checkpoint inhibitor-related toxicities does not seem to hinder responses or durability of responses in the majority of patients who discontinue treatment because of immune-related adverse events at induction. The merits, liability, and optimal duration of ongoing anti-PD-1 therapy after discontinuing induction therapy because of immune-related adverse events will require prospective evaluation.”

The predictive utility of early-onset immune-related adverse events also requires further study, Carlino and Sandhu added.

Clinical trials of combined nivolumab-ipilimumab therapy for advanced melanoma showed that about 40% of patients discontinued induction therapy with the combination because of therapy-related adverse events. Most patients stopped before receiving the recommended four doses of therapy. The impact of early discontinuation on clinical outcomes remained unclear.

To investigate the impact of early discontinuation on outcomes, Postow and colleagues pooled data from randomized phase II and III trials involving a total of 409 patients with advanced melanoma treated with the combination of nivolumab and ipilimumab. Investigators compared treatment efficacy in 96 patients who discontinued treatment during the induction phase of therapy because of adverse events and in 233 patients who did not discontinue because of adverse events.

Investigators evaluated the safety of the combination in patients who discontinued treatment at any time because of adverse events versus those who who did not.

After a minimum follow-up for efficacy of 18 months, median PFS was 8.4 months (95% CI 5.8-16.7) in patients who discontinued induction therapy because of adverse events and 10.8 months (95% CI 5.9-23.0) in those who did not discontinue during induction therapy (P=0.97). The 18-month PFS was 38% in the patients who discontinued and 49% for those who did not. Median PFS had yet to be reached in either group (HR 0.79, 95% CI 0.54-1.17, P=0.2344).

The 18-month overall survival was 67% for patients who discontinued induction therapy because of adverse events and 62% for those who did not.

The objective response rate also did not differ significantly between patients who discontinued because of adverse events (58.3%) and patients who did not (50.2%).

The safety analysis showed that 156 of 407 (38%) patients discontinued treatment at any time because of adverse events, most of which were grade 3/4 severity. Colitis was the most common adverse event leading to discontinuation (10%), followed by elevated liver enzymes (4% to 5%). Colitis also was the most common serious adverse event leading to hospitalization (21% of all patients who discontinued treatment because of adverse events).

The most frequent grade 3/4 treatment-related adverse events associated with discontinuation at any time were gastrointestinal (especially diarrhea and colitis, 20% each). For patients who did not discontinue because of adverse events, the most common grade 3/4 adverse events were hepatic (10%).

Systemic corticosteroids were the most frequently used immunosuppressive therapy for management of adverse events, administered to 91% of patients who discontinued nivolumab-ipilimumab combination therapy because of adverse events and 55% of those who did not discontinue.

The study was supported by Bristol-Myers Squibb and the National Cancer Institute.

Postow disclosed relationships with Bristol-Myers Squibb, Marck, Amgen, Novartis, Array BioPharma, Infinity Pharmaceuticals, and RGenix. All of the coauthors disclosed relationships with one or more healthcare industry company.

Carlino disclosed relationships with Bristol-Myers Squibb, Merck, Amgen, Novartis, and Pierre Fabre. Sandhu disclosed relationships with Merck, Bristol-Myers Squibb, Amgen, and Janssen.


Tagged with:

About author

Related Articles